Isarna Therapeutics Is A Clinical Stage Biotech Companyheadquartered In Munichgermanyisarna Develops Isth0036A Next Generation Antisense To Block Tgf Beta 2 Productiona Key Molecule In The Pathogenesis Of Retinal Diseasecurrent Therapies Aeapproved And Pipeline Products Aemostly Target The Edemawith Several Anti Vegfs Approved Or In Development Offering Only Minor Improvements Over Current Socwhile Anti Vegf Is A Very Effective Therapy Aeit Does Not Stop The Disease Progression Of Retinal Pathologies Like W Amdpatients Progress To Late Stage Disease Despite Effective Anti Edema Therapy Aeand Thus Develop Fibrosistgf B Is A Key Driver Of Fibrosisso Blocking The Production Of This Molecule Intracellularlyusing Elaborated Antisense Moleculespromises To Be A Game Changer In Retina Therapyanimal Data Show Comparable Efficacy Of Isth0036 To Block Neovascularization As Anti Vegf Aewith The Added Benefit Of Suppressing Fibrosisthis Moa Could Be An Effective Long Term Treatment In Several Retinal Pathologies Including The Blockbuster Indications Wamddmervowith A Significant Upward Potential In Dry Amd A Phase 1 Study Showed Excellent Safetyisarna Therapeutics Is Currently Preparing A Phase 2A Study In Wet Amd And In Dme Dr Isarna Is Led By A Highly Experienced Managementthe Coorene Ra Ckertmdmba Led At Bayer Novartis The Global Development Of Both Approved Blockbuster Drugs For Retinal Diseases Aeeylea And Lucentisthe Cmoprofmarion Munkmdphd Is A Leading Global Retina Specialist Isarna Is Open To Discuss Future Partnering For The Development And Is Seeking Investors To Finance The Clinical Development And Growth Of The Company
No conferences found for this company.
| Company Name | Isarna Therapeutics Gmbh |
| Country |
Germany
|
| Address | N/A |
| Telephone | N/A |
| N/A |
